The association between cardiovascular risk and cardiovascular magnetic resonance measures of fibrosis: the Multi-Ethnic Study of Atherosclerosis (MESA) by unknown
Yi et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:15 
DOI 10.1186/s12968-015-0121-5RESEARCH Open AccessThe association between cardiovascular risk and
cardiovascular magnetic resonance measures of
fibrosis: the Multi-Ethnic Study of Atherosclerosis
(MESA)
Colin J Yi1, Colin O Wu8, Michael Tee1, Chia-Ying Liu1, Gustavo J Volpe2, Martin R Prince3, Gregory W Hundley4,
Antoinette S Gomes5, Rob J van der Geest6, Susan Heckbert7, João A Lima2 and David A Bluemke1,2*Abstract
Background: Risk scores for cardiovascular disease (CVD) are in common use to integrate multiple cardiovascular
risk factors in order to identify individuals at greatest risk for disease. The purpose of this study was to determine if
individuals at greater cardiovascular risk have T1 mapping indices by cardiovascular magnetic resonance (CMR)
indicative of greater myocardial fibrosis.
Methods: CVD risk scores for 1208 subjects (men, 50.8%) ages 55–94 years old were evaluated in the Multiethnic Study
of Atherosclerosis (MESA) at six centers. T1 times were determined at 1.5Tesla before and after gadolinium administration
(0.15 mmol/kg) using a modified Look-Locker pulse sequence. The relationship between CMR measures (native T1, 12
and 25 minute post-gadolinium T1, partition coefficient and extracellular volume fraction) and 14 established different
cardiovascular risk scores were determined using regression analysis. Bootstrapping analysis with analysis of variance was
used to compare different CMR measures. CVD risk scores were significantly different for men and women (p < 0.001).
Results: 25 minute post gadolinium T1 time showed more statistically significant associations with risk scores (10/14
scores, 71%) compared to other CMR indices (e.g. native T1 (7/14 scores, 50%) and partition coefficient (7/14, 50%) in
men. Risk scores, particularly the new 2013 AHA/ASCVD risk score, did not correlate with any CMR fibrosis index.
Conclusions: Men with greater CVD risk had greater CMR indices of myocardial fibrosis. T1 times at greater delay time
(25 minutes) showed better agreement with commonly used risk score indices compared to ECV and native T1 time.
Clinical trial registration: http://www.mesa-nhlbi.org/, NCT00005487.
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Overt cardiovascular disease (CVD) encompasses a wide
array of late stage outcomes (e.g., coronary heart disease,
heart failure, myocardial infarction) that are expensive to
treat and that may be preventable. In order to better man-
age cardiovascular health, CVD risk models have been de-
veloped to relate an individual’s risk for adverse CVD
outcomes with various biomarkers [1,2]. The Framingham* Correspondence: bluemked@nih.gov
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CVD into an overall quantitative assessment of risk score
[3]. Risk score models such as Framingham include vari-
ous combinations of age, gender, blood pressure, etc. using
different weighting coefficients for each risk parameter.
High risk individuals may be subject to more intensive
assessment and therapy [4]. Recent efforts to further
improve primary CVD prevention have led to the develop-
ment of the new 2013 AHA guidelines [5]. Imaging is in-
creasingly used to phenotype patients. For example, theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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calcium score has been previously studied [6].
The myocardium responds to physiological and patho-
logical stress by remodeling with increased deposition of
interstitial collagen [7]. The presence of diffuse myocardial
fibrosis has been known to confer risk for various types of
CVD [8], and common traditional cardiovascular risk fac-
tors are known to be associated with myocardial fibrosis
[9-12]. One noninvasive method to assess diffuse myocar-
dial fibrosis is by measuring the T1 relaxivity of myocardial
tissue before and/or after administration of a gadolinium
based contrast agent using cardiovascular magnetic reson-
ance (CMR) [13,14]. The rate of contrast relaxation is
dependent on the inherent tissue properties of the myo-
cardium, thus allowing characterization of myocardial
composition. Extracellular volume (ECV) is an additional
index of fibrosis that is related to the ratio of interstitial
space to total myocardial volume [15]. T1 and ECV indices
of myocardial fibrosis have been validated in select patient
populations [16,17].
CMR indices of myocardial fibrosis are relatively new
biomarkers and their applicability in a general, low to
moderate risk population has not yet been determined.
The Multi-Ethnic Study of Atherosclerosis (MESA) study
provides the opportunity to explore the validity of CMR
indices of myocardial fibrosis with respect to risk for CVD
in a largely asymptomatic subject pool. The purpose of
this study was to determine the relationship between
CMR fibrosis indices and CVD risk score models in a
large, population-based study. We hypothesize CVD risk
scores will be correlated with CMR fibrosis indices.Methods
Details of the design and organization of the Multi-Ethnic
Study of Atherosclerosis (MESA) trial have been re-
ported previously [18]. From 2000–2002, 6814 men and
women ranging from ages of 45 to 84 years were en-
rolled in the baseline MESA study. MESA participants
were community-dwelling men and women, of African
American, Hispanic, white and Chinese American des-
cent. Study subjects underwent continued follow up for at
periodic intervals, and CMR was performed at the 5th
follow-up examination from 2010–2012 (designated as the
“MESA 5” follow-up examination). Institutional review
board approval was obtained and all subjects signed in-
formed consent for MESA procedures.
Smoking was defined as never, former (smoked ≥ 100
cigarettes in lifetime), or current (smoked cigarettes in last
30 days). Hypertension was defined as systolic blood pres-
sure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg,
self-reported hypertension or use of antihypertensive
medication. Hypertrophy of the left ventricle was defined
as “no” (absence of LV hypertrophy) or “yes” (presence ofLV hypertrophy). Type II diabetes was defined as fasting
glucose > 125 mg/dl or use of diabetic medication.
Lipid, lipoprotein, and other laboratory assays
Blood was drawn after a 12 hour fast, and samples were
stored at −70°C. Lipids, insulin, and glucose were mea-
sured at a central laboratory (Collaborative Studies Clin-
ical Laboratory at Fairview University Medical Center,
Minneapolis, Minnesota). Lipids were assayed on thawed
EDTA plasma within 2 weeks of sample collection, using
Centers for Disease Control Prevention/NHLBI standards.
High-density lipid cholesterol (HDL-C) was measured
using the cholesterol oxidase method (Roche Diagnostics,
Indianapolis, Indiana) after precipitation of non-HDL-C
with magnesium/dextran (coefficient of variation 2.9%).
LDL-C was calculated using Friedewald equation [19].
The serum concentration of NT-proBNP was measured
using a highly sensitive and specific immunoassay based
on a double-antibody sandwich technique (Roche Diag-
nostics Corporation, Indianapolis, IN, USA) [20].
CMR for evaluation of diffuse fibrosis
Study subjects with prior myocardial infarction or focal
late gadolinium enhancement were excluded from ana-
lysis. The CMR and T1 mapping protocol in MESA has
been described [21]. Pre-contrast short axis (Modified
Look Locker Inversion Recovery) MOLLI imaging at the
mid ventricle was obtained followed by post-contrast
image acquisition 12 and 25 min after contrast injection.
The MOLLI sequence acquired a set of 11 source images
over 17 heartbeats. An inversion recovery echo triggered
sequence consisted of 3 inversion pulses at the following
inversion times: 100, 200, and 350 ms. Additional scanning
parameters were summarized as follows: flip angle = 35°;
repetition time = 2.2 ms; echo time = 1.1 ms; field of
view = 360 × 360 mm; matrix = 192 × 183; slice thick-
ness = 8 mm; generalized autocalibrating partially paral-
lel acquisitions factor = 2.
MASS research software (Department of Radiology,
Leiden University Medical Center, Leiden, and the
Netherlands) was used to create T1 maps. Levenberg-
Marquardt algorithm allowed a 3 parameter curve fit
using MOLLI as a source image to extract T1 time for
each pixel. Myocardial T1 time was then determined by
careful drawing of the region of interest to encompass
the myocardium tissue only, so that the trabeculation,
blood pool and epicardial fat were excluded. The partition
coefficient (λ) was calculated by using a 3 point linear fit
to determine the resulting slope (ΔT1myo/ΔT1blood). Extra-
cellular volume (ECV) as a percentage was evaluated by
multiplying the partition coefficient by (1 – hematocrit).
Expected associations with greater degree of myocardial
fibrosis by CMR are higher ECV and native T1 time, but
lower post gadolinium T1 time [15-17].
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Risk scores were based on prior systematic and blinded
review by Allan et al. [22], including Edinburgh (CVD),
Edinburgh (CHD), BNF, ASSIGN, PROCAM, Framingham,
National Cholesterol Education Program, and Reynolds
Risk Score (Table 1). In addition, Framingham and 5 other
risk scores (MI risk score, stroke risk score, death from
CHD and CVD risk scores, MESA derived risk score, and
the new AHA/ASCVD risk score) were available for each
MESA 5 subject [5,23,24]. The endpoints used for each of
the risk scores are shown in Table 1.
Statistical analysis
All analyses were stratified by gender to reduce the ef-
fects of potential confounders. Risk scores were catego-
rized as a) “low”, “intermediate” and “high”, or b) “low”,
“average”, “intermediate” and “high” depending on the
conventions of each score [26]. However, for evaluation
of association between each of the 14 risk scores and T1
times or ECV, the risk scores were treated as continuous
variables. Correlations between each risk score and T1
times or ECV were tested using linear regression models
adjusted for heart rate. T1 times were studied at both 12
and 25 minutes after gadolinium administration. The
Generalized Additive Model (GAM) was employed to
test for departures from the linear regression models. IfTable 1 Endpoint prediction for each of 14 risk scores
Risk scores* Endpoint prediction Ris
Edinburgh (CHD)1 10 year CHD Ag
Edinburgh (CVD)1 10 year CVD Ag
Death (CHD)1 10 year death from
CHD
Ag
Death (CVD)1 10 year death from
CVD
Ag
Myocardial Infarction (MI)1 10 year MI Ag
Stroke1 10 year stroke Ag
Framingham (CVD)3 10 year CVD Ag
National Cholesterol Education Program
(NCEP)4
10 year CHD Ag
British National Formulary (BNF)1 10 year CVD Ag
ASSIGN1 10 year CVD Ag
PROCAM2 10 year CHD Dia
Reynolds5 10 year CHD Ag




10 year CVD Ag
*References indicated below.
CVD – Cardiovascular Disease; CHD – Coronary Heart Disease; HF – Heart Failure; Ch
Pressure; HTN Med – Hypertension Medication; MI Fam – Family History of Myocard
Trig – triglycerides; BMI – body mass index; CRP – c reactive protein.
‡Risk Scores were calculated as in [25].
1-7See Appendix for Risk score references.the resulting model suggested non-linearity, the corre-
sponding data points were refitted using a linear spline
regression model. Bootstrapping analysis was performed
with 10,000 iterations to test for reliability of correlation
results [27].
Results
Complete CMR data as well as clinical and serologic
data were available (Table 2) for 1231 subjects (625
(50.8%) women and 606 (49.2%) men). Characteristics of
the MESA 5 population are shown in Table 2. Age and
BMI were not significantly different between men and
women. The racial composition included Caucasians
(51.7%), African Americans (22.5%), Hispanic (14.1%),
and Chinese Americans (11.7%). 6.8% of study subjects
were current smokers. The prevalence of hypertension
and diabetes was 52.1% and 15%, respectively. All sub-
jects were free from prior myocardial infarction or CVD
event at the time of MESA exam 5.
As expected, CVD risk scores were generally greater
for men than women (Table 3). Tables 4, 5, 6, 7 and 8
present the associations between the 14 risk scores and
CMR measures of fibrosis, including 12 and 25 min post
gadolinium T1 time, native T1, partition coefficient and
ECV. Table 5 shows that that 10 of 14 (71%) risk score
models (Edinburgh CVD and CHD, MI, stroke, CVDk factors included in model‡
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, SBP, Chol, HDL, HTN Med
e, Smoker, Diabetes, SBP, HDL, LDL
e, Gender, Smoker, Diabetes, LVH, SBP, Chol, HDL
e, Gender, Smoker, Diabetes, SBP, Chol, HDL, Cigarettes, MI Fam
betes, SBP, HDL, LDL, Trig, Glucose, HTN Med
e, Gender, Smoker, Diabetes, SBP, Chol, HDL, CRP, Hemoglobin, MI Fam
e, Gender, Smoker, BMI Grade, SBP, Heart Rate, Diabetic Status, BNP, LV
ss
e, Gender, Smoker, Diabetes, SBP, Chol, HDL
ol – Total Cholesterol; LVH – Left Ventricular Hypertrophy; SBP – Systolic Blood
ial Infarction; BNP – proBNP levels; LV Mass – Left Ventricular Mass;
Table 2 Characteristics of study population
Demographics Women (n = 625) Men (n = 606) p-value
Age (yrs) 67 ± 9 67 ± 9 0.94
Height (cm) 160 ± 6.6 174 ± 7.5 <0.001
Weight (lb) 161 ± 36 188 ± 35 <0.001
BMI (kg/m2) 28 ± 6 28 ± 5 0.24
White/African/Chinese/Hispanic (%) 54/23/11/12 50/22/12/16 0.13
Heart rate (beats/min) 65.3 ± 9.5 63.8 ± 10 0.005
Systolic blood pressure (mm Hg) 122 ± 20 121 ± 18 0.49
Diastolic blood pressure (mm Hg) 65 ± 9 71 ± 9 <0.001
Current smokers 41 (6.6) 43 (7.1) <0.001
Hypertension 343 (54.9) 298 (49.2) 0.045
Diabetes 87 (13.9) 98 (16.2) 0.002
Metabolic syndrome‡ 233 (37.3) 182 (30) 0.001
HDL cholesterol (mg/dl) 60.2 ± 16.9 49.1 ± 13.1 <0.001
LDL cholesterol (mg/dl) 110.8 ± 31.2 100.6 ± 30.4 <0.001
Total cholesterol (mg/dl) 193.2 ± 34.6 171.5 ± 34 <0.001
Triglycerides (mg/dl) 111.8 ± 58.7 110 ± 69 0.78
eGFR (ml/min/1.73 m2) 85 ± 21 85 ± 17 0.52
Framingham risk score 0.06 ± 0.04 0.13 ± 0.07 <0.001
Native (Pre-contrast) myocardial T1 (ms) 986 ± 45 968 ± 38 <0.001
Post-contrast myocardial T1 (ms)
§ 505 ± 41 535 ± 34 <0.001
Hematocrit (%) 38.4 ± 2.9 41.6 ± 3.5 <0.001
Extracellular volume fraction (%)ǁ 28.1 ± 2.8 25.8 ± 2.9 <0.001
*Values are mean ± SD, %, or n (%).
BMI = body mass index; eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein, LDL = low-density lipoprotein.
‡Defined according to National Cholesterol Education Program guidelines.
§25-min post-contrast T1 time.
ǁn = 321 for women; n = 287 for men.
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mingham) showed greater risk score associated with
lower post-gadolinium T1 time at 25 minutes in men.
The partition coefficient and native T1 times were each
associated with 7 risk scores in men (although 1 case of
opposite than expected correlation for each). ECV and
12 min T1 time were each associated with 3 risk scores
in men occurring in the expected direction (i.e., greater
cardiovascular risk correlated with greater fibrosis by
CMR). The overall agreement between risk scores and
CMR indices is shown in Figure 1.
For women, only the MESA and Reynolds risk scores
were significantly associated with both T1 time and ECV
CMR metrics. Both MESA and Reynolds risk score showed
inverse associations with post-contrast T1 time (i.e., greater
fibrosis) in men (p = 0.008 and <0.001, respectively). ECV
was positively associated with both MESA and Reynolds
risk score (p = 0.001 and p = 0.013, respectively).
Most of the risk scores showed low to moderate
changes in T1 time or ECV per unit change in risk per-
centage. Nonlinear GAM models resulted in improvedcorrelation between the Reynolds risk score and 25 mi-
nute T1 time in men (p = 0.011). Similarly, non-linear as-
sociation was observed for MESA risk score with
25 minute T1 time in men (p = 0.009). Table 9 summa-
rizes these findings. Overall, these adjustments magnify
the strength of correlations between either T1 times or
ECV with risk scores below a predefined threshold de-
termined using GAM analysis.
Discussion
Risk scores predicting endpoints for men and women
without symptomatic CVD are an increasingly important
tool to help identify individuals who may benefit from
more intensive or earlier medical intervention. Most risk
models use similar risk factors to predict cardiovascular
events (Table 2) and thus these models may be expected
to show similar trends in relationship to CMR fibrosis.
Greater CVD risk by most risk scores (10/14, 71%) was
associated with greater myocardial fibrosis (25 min T1
time) as identified by CMR in men (Figure 1). T1 times
(25 min) showed improved relationship to CVD risk
Table 3 Cardiovascular risk score (%) for outcomes* for
men and women
Risk score Women Men p-value
Edinburgh (CHD) 5.772 ( 4.275 ) 12.786 ( 7.034 ) <0.001
- 552/51/12 226/300/72 –
Edinburgh (CVD) 11.629 ( 8.233 ) 19.339 ( 10.1 ) <0.001
- 337/197/81 98/253/247 –
Death (CHD) 1.204 ( 1.936 ) 3.455 ( 3.159 ) <0.001
- 610/5/0 571/25/2 –
Death (CVD) 3.481 ( 5.027 ) 6.398 ( 6.583 ) <0.001
- 563/41/11 477/97/24 –
MI 1.819 ( 2.282 ) 5.944 ( 4.34 ) <0.001
- 605/10/0 512/80/6 –
STROKE 3.017 ( 3.553 ) 3.614 ( 3.542 ) 0.003
- 590/20/5 565/29/4 –
Framingham (CVD) 10.696 ( 8.223 ) 25.221 ( 13.78 ) <0.001
- 378/167/72 62/184/356 –
NCEP 10.583 ( 6.144 ) 11.088 ( 6.365 ) 0.162
- 349/212/50 328/210/55 –
BNF 8.789 ( 6.874 ) 16.4 ( 9.959 ) <0.001
- 446/134/35 150/300/148 –
ASSIGN 13.222 ( 30.631 ) 88.814 ( 29.171 ) <0.001
- 264/13/96 36/9/516 –
PROCAM 0.407 ( 0.608 ) 0.476 ( 0.514 ) 0.033
- 613/0/0 599/0/0 –
Reynolds 3.711 ( 4.837 ) 12.377 ( 9.688 ) <0.001
- 549/26/9 293/177/89 –
MESA 2.888 ( 6.518 ) 2.854 ( 6.758 ) 0.935
- 480 / 14 / 13 471/19/10 –
ASCVD 10.116 ( 9.8 ) 14.61 ( 8.895 ) <0.001
- 258/111/49 138/159/82 –
*Risk scores and outcomes are defined in Table 1.
Bold indicates p < 0.05.
Below each risk score shows number of subjects categorized as “low”/“medium”/
“high” risk.
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native and 12 min T1 time. For women, who are gener-
ally categorized as lower risk than men in CVD models,
there was generally little or no relationship between
CVD risk score and T1 time or ECV.
Risk scores generally have similar endpoint prediction
encompassing the likelihood of having coronary artery
disease (CAD) that in turn may lead to heart attack and/
or heart failure in late stage disease. We hypothesized
that this propensity for cardiovascular disease may in
turn be related to the development of diffuse myocardial
fibrosis. Several previous studies have looked at the
agreement amongst various risk scores, including those
ones used for the current study. This study sought toindirectly look at agreement between any two risk scores
based on their respective effect size and significance of
associations with CMR indices. This agreement test as-
sures a consistent comparison between risk scores. As in
our study (Table 3), there was low agreement between
any two of these risk scores as been reported, presum-
ably due to the population dependence of these risk
score estimates. However, each risk score has its own
utilization scheme for its targeted population. Blending
multiple risk scores together to have a single measure of
risk for all subjects will unnecessarily de-emphasize the
importance of some risk factors. Thus, we sought to
evaluate a wide range of risk score methods in relation-
ship to CMR indices of fibrosis.
CMR measures of diffuse myocardial fibrosis are rela-
tively new, and long term validation in relationship to
cardiovascular outcomes in a general population has not
been performed. At present, there is little consensus re-
garding the ‘optimum’ CMR measure to quantify the de-
gree of fibrosis especially in asymptomatic subjects. The
partition coefficient is the slope of the linear relationship
between myocardium relaxivity (1/ T1) vs. blood relaxiv-
ity before and after gadolinium administration [28]. The
myocardial volume of distribution of gadolinium, or
extracellular volume fraction (ECV), is derived from the
partition coefficient by dividing by (1-hematocrit). ECV
and partition coefficient seek to reflect the underlying
correlates of diffuse myocardial fibrosis, i.e. expansion of
the extracellular matrix. There are however multiple T1
measurements in the ECV calculation, each with its own
error/variability in measurement. In contrast, change in
T1 time is nonspecific as to etiology and does not en-
tirely reflect myocardial fibrosis. Indeed, increased native
T1 time and ECV have been reported in amyloid light
chain disease and low T1 times have been reported in
Fabry disease [29,30].
Our results were somewhat surprising, in that a ‘nor-
malized’ T1 measure such as ECV might have been ex-
pected to perform better in relationship to risk scores
compared to the 25 minute or other T1 measures. The
exact reasons for this are primarily conjectural. Certainly
most information about T1 measures to date derives
from patients with clinical cardiovascular disease. For
asymptomatic subjects, CVD risk factors such as hyper-
tension (~50% of our study cohort), smoking, diabetes
and age are probably those which may be most strongly
related to myocardial fibrosis [9-12]. Myocardial fibrosis
is a result of a pathologic process that involves extracel-
lular matrix remodeling due to a wide array of causes:
inflammation, excessive myocardial stretch, oxidative
stress, and glycation products particularly from diabetic
individuals [31]. Over time, the presence of myocardial
fibrosis alters the myocyte arrangement in cardiac cells,
thereby degrading the structure and function of the
Table 4 Regression coefficients (β) between cardiovascular risk score and 12 minute post gadolinium T1 time
Risk score β (msec/%) women/men†‡ CI (95%) women/men† p-value women/men*†
Edinburgh (CHD) −0.343 / -0.288 [ −1.116 to 0.43 ] / [ −0.668 to 0.093 ] 0.383 / 0.138
Edinburgh (CVD) −0.154 / -0.244 [ −0.556 to 0.248 ] / [ −0.509 to 0.021 ] 0.453 / 0.071
DEATH (CHD) −0.011 / -0.701 [ −1.718 to 1.697 ] / [ −1.549 to 0.147 ] 0.99 / 0.105
DEATH (CVD) 0.083 / -0.5 [ −0.574 to 0.741 ] / [ −0.906 to −0.094 ] 0.804 / 0.016
MI −0.67 / -0.453 [ −2.12 to 0.78 ] / [ −1.072 to 0.165 ] 0.365 / 0.151
STROKE −0.054 / -0.541 [ −0.984 to 0.876 ] / [ −1.298 to 0.215 ] 0.909 / 0.16
Framingham (CVD) −0.119 / -0.206 [ −0.522 to 0.284 ] / [ −0.398 to −0.013 ] 0.562 / 0.037
NCEP −0.045 / -0.058 [ −0.587 to 0.496 ] / [ −0.484 to 0.368 ] 0.869 / 0.789
BNF −0.147 / -0.212 [ −0.628 to 0.334 ] / [ −0.481 to 0.057 ] 0.548 / 0.122
ASSIGN −0.038 / -0.006 [ −0.146 to 0.07 ] / [ −0.098 to 0.087 ] 0.492 / 0.907
PROCAM −2.578 / -2.131 [ −8.041 to 2.885 ] / [ −7.328 to 3.067 ] 0.354 / 0.421
Reynolds −0.504 / -0.339 [ −1.187 to 0.179 ] / [ −0.617 to −0.061 ] 0.148 / 0.017
MESA 0.126 / -0.391 [ −0.437 to 0.689 ] / [ −0.832 to 0.05 ] 0.661 / 0.082
ASCVD −0.102 / -0.138 [ −0.505 to 0.301 ] / [ −0.497 to 0.22 ] 0.62 / 0.449
*Bold indicates p < 0.05.
†Data represented as regression coefficient for women/men.
‡β = regression coefficient expressed as ms/per unit % change in risk score.
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physiologically in tandem with the underlying pathology
of myocardial fibrosis.
Of several possibilities, it is possible that a greater
post gadolinium delay time (i.e. at 25 minutes) discrim-
inates fibrosis and is relatively more reproducible in a
multi-center setting, and thus more reliably related to
cardiovascular risk factors compared to other T1 times.
Nevertheless, it seems reasonable that CMR investiga-
tors continue to consider multiple T1 indices and thatTable 5 Regression coefficients (β) between cardiovascular ris
Risk score β (msec/%) women/men†‡ CI (
Edinburgh (CHD) −0.175 / -0.485 [ −0
Edinburgh (CVD) −0.169 / -0.412 [ −0
DEATH (CHD) −0.44/-1.275 [ −2
DEATH (CVD) −0.215 / -0.798 [ −0
MI −0.12 / -0.783 [ −1
STROKE −0.27 / -1.067 [ −1
Framingham (CVD) −0.173 / -0.342 [ −0
NCEP 0.123 / -0.362 [ −0
BNF −0.14 / -0.377 [ −0
ASSIGN −0.023 / 0.026 [ −0
PROCAM −0.058 / -2.441 [ −5
Reynolds −0.335 / -0.554 [ −1
MESA 0.004 / -0.716 [ −0
ASCVD −0.099 / -0.307 [ −0
*Bold indicates p < 0.05.
†Data represented as regression coefficient for women/men.
‡β = regression coefficient expressed as ms/per unit % change in risk score.the optimal T1 index may vary by disease and/or condi-
tion being evaluated.
Since CVD risk models have been validated in various
cohorts, it is reasonable to question if individuals
deemed at higher CVD risk may have greater fibrosis
indices by CMR. A critical factor in this analysis is
whether CMR is sensitive enough to evaluate early myo-
cardial fibrosis that might be predicted using these CVD
risk calculators. Indeed, in men, this does appear to be
the case: 10/14 CVD risk scores showed lower post-k score and 25 minute post gadolinium T1 time
95%) women/men† p-value women/men*†
.939 to 0.589 ] / [ −0.88 to −0.089 ] 0.654 / 0.016
.566 to 0.229 ] / [ −0.687 to −0.136 ] 0.405 / 0.003
.126 to 1.246 ] / [ −2.156 to −0.395 ] 0.608 / 0.005
.864 to 0.434 ] / [ −1.218 to −0.378 ] 0.515 / <0.001
.553 to 1.313 ] / [ −1.427 to −0.14 ] 0.87 / 0.017
.188 to 0.649 ] / [ −1.854 to −0.28 ] 0.564 / 0.008
.572 to 0.225 ] / [ −0.542 to −0.142 ] 0.393 / 0.001
.414 to 0.659 ] / [ −0.807 to 0.083 ] 0.654 / 0.111
.615 to 0.335 ] / [ −0.656 to −0.098 ] 0.564 / 0.008
.129 to 0.083 ] / [ −0.07 to 0.122 ] 0.666 / 0.598
.48 to 5.365 ] / [ −7.861 to 2.979 ] 0.983 / 0.377
.008 to 0.339 ] / [ −0.839 to −0.268 ] 0.329 / <0.001
.562 to 0.57 ] / [ −1.241 to −0.191 ] 0.99 / 0.008
.492 to 0.293 ] / [ −0.694 to 0.08 ] 0.619 / 0.12
Table 6 Regression coefficients (β) between cardiovascular risk score and native T1 time
Risk score β (msec/%) women/men†‡ CI (95%) women/men† p-value women/men*†
Edinburgh (CHD) 0.248 / 0.118 [ −0.588 to 1.085 ] / [ −0.318 to 0.553 ] 0.56 / 0.596
Edinburgh (CVD) 0.286 / 0.32 [ −0.148 to 0.72 ] / [ 0.017 to 0.623 ] 0.196 / 0.038
DEATH (CHD) 0.618 / 0.611 [ −1.229 to 2.464 ] / [ −0.359 to 1.582 ] 0.511 / 0.216
DEATH (CVD) 0.268 / 0.565 [ −0.443 to 0.979 ] / [ 0.101 to 1.029 ] 0.459 / 0.017
MI 1.198 / 0.241 [ −0.368 to 2.765 ] / [ −0.467 to 0.949 ] 0.134 / 0.504
STROKE 0.578 / 1.345 [ −0.428 to 1.583 ] / [ 0.485 to 2.205 ] 0.26 / 0.002
Framingham (CVD) 0.374 / 0.284 [ −0.061 to 0.809 ] / [ 0.062 to 0.505 ] 0.092 / 0.012
NCEP 0.457 / 0.12 [ −0.128 to 1.041 ] / [ −0.366 to 0.606 ] 0.126 / 0.628
BNF 0.25 / 0.229 [ −0.269 to 0.77 ] / [ −0.079 to 0.536 ] 0.344 / 0.145
ASSIGN −0.039 / -0.169 [ −0.159 to 0.081 ] / [ −0.275 to −0.062 ] 0.523 / 0.002
PROCAM 5.3 / -3.063 [ −0.604 to 11.204 ] / [ −9.027 to 2.9 ] 0.078 / 0.313
Reynolds 0.252 / 0.495 [ −0.51 to 1.015 ] / [ 0.172 to 0.819 ] 0.516 / 0.003
MESA 0.238 / 0.398 [ −0.357 to 0.833 ] / [ −0.112 to 0.908 ] 0.433 / 0.126
ASCVD 0.302 / 0.423 [ −0.141 to 0.744 ] / [ 0.006 to 0.84 ] 0.181 / 0.047
*Bold indicates p < 0.05.
†Data represented as regression coefficient for women/men.
‡β = regression coefficient expressed as ms/per unit % change in risk score.
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interest, ECV appeared to be less sensitive than post
gadolinium T1 time in this regard. In the same fashion,
native T1 time was also less sensitive than post-
gadolinium T1 time. In women, little or no relationship
was noted using the CMR indices. One reason for this
may be substantially lower levels of both CVD risk and
thus lower degrees of myocardial fibrosis in women
compared to men.Table 7 Regression coefficients (β) between cardiovascular ris
Risk score β (msec/%) women/men†‡ CI (95%)
Edinburgh (CHD) −0.00053 / 0.00001 [ −0.0012
Edinburgh (CVD) −0.00006 / 0.00029 [ −0.0004
DEATH (CHD) −0.00049 / 0.00049 [ −0.0021
DEATH (CVD) −0.00019 / 0.0007 [ −0.0008
MI 0.00031 / 0.00004 [ −0.0011
STROKE −0.00024 / 0.00098 [ −0.0011
Framingham (CVD) −0.00011 / 0.00032 [ −5e-04
NCEP −0.00003 / -0.00025 [ −0.0005
BNF −0.00027 / 0.00013 [ −0.0007
ASSIGN −0.00007 / -0.00013 [ −0.0001
PROCAM 0.00324 / -0.00428 [ −0.0021
Reynolds −0.00016 / 0.00047 [ −0.0008
MESA −0.00007 / 0.00067 [ −0.0006
ASCVD −0.00002 / 0.00048 [ −0.0004
*Bold indicates p < 0.05.
†Data represented as regression coefficient for women/men.
‡β = regression coefficient expressed as ms/per unit % change in risk score.The newly released risk score ASCVD 2013 showed
poor correlation with T1 time and ECV for both men
and women. Relative to the older risk scores, this new
risk score reclassified substantial number of MESA sub-
jects as “high risk”. This reclassification to high risk
levels has been a major criticism of the new ASCVD risk
score. Based on our CMR data, the new ASCVD score
was not associated with CMR detected myocardial
fibrosis.k score and partition coefficient (λ)
women/men† p-value women/men*†
9 to 0.00023 ] / [ −0.00046 to 0.00047 ] 0.168 / 0.980
5 to 0.00033 ] / [ −3e-05 to 0.00061 ] 0.764 / 0.080
6 to 0.00118 ] / [ −0.00054 to 0.00152 ] 0.566 / 0.350
3 to 0.00046 ] / [ 0.00021 to 0.00119 ] 0.568 / 0.005
1 to 0.00173 ] / [ −0.00071 to 8e-04 ] 0.664 / 0.908
5 to 0.00067 ] / [ 6e-05 to 0.00189 ] 0.608 / 0.037
to 0.00028 ] / [ 8e-05 to 0.00055 ] 0.579 / 0.008
6 to 5e-04 ] / [ −0.00077 to 0.00027 ] 0.924 / 0.348
4 to 2e-04 ] / [ −2e-04 to 0.00045 ] 0.262 / 0.448
8 to 4e-05 ] / [ −0.00024 to -2e-05 ] 0.214 / 0.024
to 0.00858 ] / [ −0.01063 to 0.00208 ] 0.234 / 0.187
5 to 0.00053 ] / [ 0.00014 to 8e-04 ] 0.645 / 0.006
1 to 0.00047 ] / [ 0.00014 to 0.00121 ] 0.799 / 0.013
4 to 4e-04 ] / [ 3e-05 to 0.00093 ] 0.914 / 0.035
Table 8 Regression coefficients (β) between cardiovascular risk score and extracellular volume fraction (ECV)
Risk score β (msec/%) women/men†‡ CI (95%) women/men† p-value women/men*†
Edinburgh (CHD) −0.072 / -0.012 [ −0.142 to −0.002 ] / [ −0.059 to 0.035 ] 0.043 / 0.612
Edinburgh (CVD) −0.013 / 0.014 [ −0.051 to 0.025 ] / [ −0.019 to 0.047 ] 0.497 / 0.397
DEATH (CHD) −0.035 / 0.013 [ −0.2 to 0.131 ] / [ −0.09 to 0.116 ] 0.68 / 0.806
DEATH (CVD) 0.004 / 0.056 [ −0.053 to 0.062 ] / [ 0.007 to 0.105 ] 0.88 / 0.025
MI −0.05 / -0.023 [ −0.199 to 0.098 ] / [ −0.097 to 0.05 ] 0.506 / 0.532
STROKE −0.012 / 0.086 [ −0.106 to 0.082 ] / [ −0.007 to 0.178 ] 0.805 / 0.069
Framingham (CVD) −0.01 / 0.022 [ −0.051 to 0.031 ] / [ −0.002 to 0.046 ] 0.618 / 0.071
NCEP 0.003 / -0.035 [ −0.047 to 0.052 ] / [ −0.087 to 0.017 ] 0.921 / 0.184
BNF −0.033 / 0.005 [ −0.079 to 0.012 ] / [ −0.028 to 0.038 ] 0.151 / 0.777
ASSIGN −0.007 / -0.016 [ −0.018 to 0.003 ] / [ −0.027 to −0.005 ] 0.177 / 0.003
PROCAM −0.033 / -0.328 [ −0.538 to 0.471 ] / [ −0.906 to 0.25 ] 0.897 / 0.264
Reynolds −0.083 / 0.041 [ −0.165 to −0.002 ] / [ 0.009 to 0.073 ] 0.044 / 0.013
MESA −0.005 / 0.154 [ −0.051 to 0.04 ] / [ 0.088 to 0.22 ] 0.817 / <0.001
ASCVD 0.01 / 0.001 [ −0.026 to 0.047 ] / [ −0.04 to 0.042 ] 0.579 / 0.957
*Bold indicates p < 0.05.
†Data represented as regression coefficient for women/men.
‡β = regression coefficient expressed as ms/per unit % change in risk score.
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MESA risk score is derived from the same cohort as our
study. Thus, it is not surprising that this score offers the
greatest correlation between risk score and CMR indices
of fibrosis. In addition, the MESA score adds more spe-
cific clinical markers to the risk score, including NT-Figure 1 Percentage of cardiovascular risk models showing significan
show expected directions of beta coefficients are shown (i.e. increased risk vs
native T1 time). For men, 25 minute post gadolinium T1 values showed the m
men are shown. ECV = extracellular volume fraction; λ = partition coefficient. BproBNP levels and LV mass index. NT-proBNP is a
strong independent predictor of outcomes in outpatients
with chronic heart failure. Furthermore, diffuse myocar-
dial fibrosis coincides with the processes leading up to
an event of heart failure, indicative of progression of T1
times and ECV. LV mass index characterizes thet relationship with CMR indices of fibrosis. Only risk models that
. lower post gadolinium T1 times or greater ECV, partition coefficient and
ost consistent relationship to cardiovascular risk scores. Only models for
ars indicate standard deviation.
Table 9 Relationship between CMR indices of fibrosis (T1, ECV) and risk score models based on linear piecewise
regression among men
Risk model CMR index β1 CI 1 (95%) p-value β2 CI 2 (95%) p-value
ASCVD Native T1* 0.941 [ −0.266 to 2.148 ] 0.123 0.398 [ −0.033 to 0.830 ] 0.070
Reynolds Post T1 (12 min) −0.241 [ −0.721 to 0.239 ] 0.322 −0.419 [ −0.838 to −0.001 ] 0.050
Reynolds Post T1 (25 min) −0.498 [ −0.879 to −0.116 ] 0.011 −0.807 [ −1.829 to 0.214 ] 0.113
MESA Post T1 (25 min) −1.152 [ −2.012 to −0.292 ] 0.009 −0.504 [ −1.590 to 0.582 ] 0.360
*T1 time: 25 min post gadolinium T1 time.
β1, β2 for T1 time: shown as msec/%.
Bold indicates p-value ≤ 0.05
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fuse fibrosis present. Potluri et al. previously have shown
the inverse relationship between LV mass and T1 changes
in more overt diseased cases such as HCM [32].
Like MESA, the Reynolds risk score is a contemporary
risk score. The Reynolds risk score includes C reactive
protein (CRP) in addition to traditional risk factors. CRP
is a nonspecific marker for inflammation, but has been
used to risk stratify subjects for cardiovascular disease.
Furthermore, Zhang et al. has shown CRP promotes ex-
pression of angiotensin II-induced collagen type I and
type III in mice [33], reflected by an increase in mRNA
expression of collagen I. Because of this indirect effect of
CRP on myocardial fibrosis, this risk factor may in some
way contribute to the consistent strong correlations be-
tween Reynolds and CMR indices.
Limitations
A limitation of the study is that the MESA subjects were
asymptomatic healthy subjects at baseline and thus at
relatively low cardiovascular risk. Nevertheless, 49% of
men and 55% of women had hypertension, and 14% had
diabetes. However a low prevalence of disease in asymp-
tomatic individuals likely results in considerable error
and thus variation in the risk prediction models (Table 3).
In addition, these results are primarily correlative, which
may lack causal interpretations in this study. The risk
models all generally take into account age, gender, smok-
ing, diabetes, blood pressure, cholesterol levels. Thus
our results are limited to the conclusion that 25 mi-
nute T1 times are most strongly related to combinations
of these risk factors. Other CMR measures (such as
ECV) may be useful indicators of fibrosis in other, more
definitive or more advanced disease states.
Conclusion
Cardiovascular risk scores are routinely implemented to
help identify patients who are at risk for subsequent car-
diovascular events. The risk factors that comprise the
risk scores have also been implicated in the development
of myocardial fibrosis. Using CMR, diffuse myocardial fi-
brosis can be quantified, and greater CMR fibrosis corre-
lated with greater CVD risk in men. These relationshipswere most prominent in the more contemporary risk
scores derived from MESA and the Reynolds study using
25 minute T1 gadolinium time as an outcome measure.
These moderate agreements between risk scores and T1
times suggest the clinical potential for CMR indices of
fibrosis to be used in complement with risk scores,
thereby adding prognostic value to patient care. How-
ever, future studies relating T1 time or ECV measure-
ments to cardiovascular events will help to further refine
the role of T1 mapping by CMR in asymptomatic
individuals.Appendix
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